AB122. MicroRNA-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence
Abstract publication Urology

AB122. MicroRNA-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence

Chuanliang Xu, Li Jiao, Zhen Deng, Yongwei Yu, Yun Li, Chun Yang, Junyi Chen, Zhiyong Liu, Gang Huang, Longcheng Li, Yinghao Sun

Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China

Abstract: Castration-resistant prostate cancer (CRPC) and its treatment are challenging issues in prostate cancer management. Here, we report that miR-663 is upregulated in CRPC tissues. Overexpression of miR-663 in prostate LNCaP cells promotes cell proliferation and invasion, neuroendocrine differentiation, and reduction in dihydrotestosterone-induced upregulation of prostate-specific antigen expression. Furthermore, results of in situ hybridization show that miR-663 expression is correlated with Gleason score and TNM stage and is an independent prognostic predictor of clinical recurrence. Together, these findings suggest that miR-663 is a potential oncomiR for CRPC and may serve as a tumor biomarker for the early diagnosis of CRPC.

Keywords: miR-663; castration-resistant prostate cancer (CRPC); prostate cancer

doi: 10.3978/j.issn.2223-4683.2014.s122

Cite this article as: Xu C, Jiao L, Deng Z, Yu Y, Li Y, Yang C, Chen J, Liu Z, Huang G, Li L, Sun Y. MicroRNA-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence. Transl Androl Urol 2014;3(S1):AB122. doi: 10.3978/j.issn.2223-4683.2014.s122

Article Options

Download Citation

Share